Exelixis | EXEL - 税前利润



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 14.53B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


税前利润 更改 日
Acadia Pharmaceuticals USD 46.47M 42.49M 2026-06
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
Amgen USD 2.08B 570M 2026-03
AstraZeneca USD 4.81B 894M 2026-06
Bayer EUR 321M 2.67B 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Cytokinetics USD -206.03M 23M 2026-03
Eisai JPY 25.28B 33.22B 2026-06
Eli Lilly USD 8.85B 583.8M 2026-03
Exelixis USD 262.68M 5.01M 2026-06
Genmab DKK 295M 221M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
Incyte USD 751.51M 407.91M 2026-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
MacroGenics USD -36.77M 21.84M 2026-03
Merck USD -3.53B 6.95B 2026-03
Moderna USD -1.33B 535M 2026-03
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 4.27B 430M 2026-06
Pfizer USD -653M 5.84B 2026-06
Puma Biotechnology USD 20.61M 24.76M 2024-09
Sanofi EUR 2B 3.16B 2026-03
Takeda JPY 162.72B 215.2B 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Xencor USD -21.92M 106.72M 2026-06